In a significant development for cancer treatment, James Stewart from Round Rock, Texas, has become the first patient in the state to receive a new bladder cancer therapy known as Inlexzo. Recently approved by the Food and Drug Administration, this innovative treatment offers hope for patients who have not responded to traditional therapies.
Stewart, an active 39-year-old who enjoys rollerblading and paddle boarding, began experiencing troubling symptoms last year. After noticing blood in his urine, he sought medical attention. Initially, doctors suspected an enlarged prostate and treated him accordingly, but his condition did not improve. A subsequent CT scan revealed the source of his issues was bladder cancer, leading to a series of treatments that included tumor removal surgery and the standard immunotherapy, Bacillus Calmette-Guérin (BCG).
The traditional treatment, while widely used for the past 50 years, proved ineffective for Stewart. After enduring painful BCG therapy, he faced the daunting possibility of bladder removal, which he described as “very scary.” Instead, he opted for the experimental Inlexzo treatment, marking a pivotal moment in his battle against cancer.
Innovative Treatment Offers New Hope
Inlexzo is a chemotherapy treatment delivered via a catheter in a tube that resembles a pretzel. The device straightens upon insertion into the bladder, where it remains for three weeks, slowly releasing medication to combat cancer cells. Following the initial three-week period, the tube is replaced. The treatment is designed to minimize pain, provided patients maintain hydration to prevent urinary tract infections.
After three months of treatment, Stewart is reportedly doing well, with no evidence of cancer, according to Dr. Carl Bischoff of Urology Austin. The new therapy boasts an impressive 82% complete response rate during treatment and a 51% response rate after one year. In contrast, BCG treatment has a recurrence rate of 40%, highlighting the potential of Inlexzo for patients with limited options.
Despite the benefits, the cost of Inlexzo poses a significant challenge. The total treatment course is approximately $900,000, which necessitated extensive negotiations with Stewart’s insurance provider for approval. This treatment is not typically the first option; it is reserved for patients who have failed BCG therapy and for whom bladder removal is not ideal due to age or lifestyle.
Understanding Bladder Cancer Risks and Symptoms
Bladder cancer is most prevalent among men over 65, with women making up only about 25% of cases. Smoking is the leading risk factor, while exposure to certain chemicals and frequent catheter use can also increase susceptibility. It ranks as the tenth most common cancer in the United States.
Common symptoms of bladder cancer include:
– Blood in urine
– Frequent urination
– Pain or burning sensation during urination
– A feeling of urgency immediately after urination
– Difficulty urinating or a weak stream
– Frequent nighttime urination
In advanced stages, symptoms can escalate to lower back pain, swelling in the feet, fatigue, loss of appetite, and weight loss.
Stewart remains optimistic as he continues to manage his condition alongside his active lifestyle, expressing gratitude for the support from friends and family. “I try to stay positive as best I can,” he stated. As more patients explore Inlexzo, there is hope that it may one day become a first-line treatment option, making a profound difference in lives affected by bladder cancer.
